Back to results
US 2021/0267986 A1Published application
Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations
AssigneeG1 Therapeutics, Inc.
InventorsJessica A. Sorrentino, Patrick Joseph Roberts, Jay Copeland Strum
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions for treating cancers with a combination of eribulin and a selective CDK4/6 inhibitor, wherein the selective CDK4/6 inhibitor reduces eribulin's effects on myelosuppression and/or myeloablation without reducing the efficacy of eribulin therapy.
Claims22
A method for treating cancer in a human comprising:
- administrating to the human an effective amount of a selective CDK4/6 inhibitor;
- and
- administering to the human an effective amount of eribulin, or a pharmaceutically acceptable salt thereof;
- wherein the CDK4/6 inhibitor is administered 4 hours or less prior to administration of eribulin;
- and wherein the selective CDK4/6 inhibitor is
- or or a pharmaceutically acceptable salt thereof.
3 more elements
A method for reducing myelosuppression in a human receiving eribulin for the treatment of a cancer comprising:
- administrating to the human an effective amount of a selective CDK4/6 inhibitor;
- and
- administering to the human an effective amount of eribulin, or a pharmaceutically acceptable salt thereof;
- wherein the CDK4/6 inhibitor is administered 4 hours or less prior to administration of eribulin;
- and wherein the selective CDK4/6 inhibitor is
- or or a pharmaceutically acceptable salt thereof.
3 more elements
Dependencies are inferred from the claim text.